Physician profile
James S Hahn
NPI 1457330292
$29,185.09
in general payments reported to CMS, 2019-2025
77 companies · $4,046 in 2025
The $4,046 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,182 · 2020: $2,739 · 2021: $3,747 · 2022: $8,210 · 2023: $3,249 · 2024: $4,012 · 2025: $4,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $33.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,273.65 |
| Education | $33.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $4,187.44 | 2022 | |
| Lilly USA, LLC | $2,436.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $2,011.99 | 2019-2025 | |
| Abbott Laboratories | $1,786.95 | 2019-2025 | Proclaim, Cardiomems |
| Janssen Pharmaceuticals, INC | $1,456.44 | 2019-2025 | Xarelto, Spravato |
| Novo Nordisk INC | $1,414.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,271.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biosense Webster, INC. | $1,213.75 | 2022-2025 | Carto 3 |
| Amgen INC. | $948.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $883.94 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.27 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $658.70 | 2019-2024 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $637.36 | 2022-2025 | |
| Pfizer INC. | $632.00 | 2019-2025 | |
| Allergan, INC. | $606.05 | 2019-2021 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $547.59 | 2022-2025 | Optimizer, Optimizer |
| Takeda Pharmaceuticals U.S.A., INC. | $534.12 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $458.39 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $450.13 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shockwave Medical, INC | $324.40 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Arbor Pharmaceuticals, INC. | $319.15 | 2019-2022 | |
| Corcept Therapeutics | $285.09 | 2025 | Korlym |
| Astellas Pharma US INC | $284.09 | 2019-2025 | Veozah |
| Abiomed | $271.60 | 2021-2022 | |
| Amarin Pharma, INC. | $256.93 | 2019-2021 | |
| Lundbeck LLC | $232.78 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $203.04 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $192.06 | 2024-2025 | Nexletol, Nexlizet |
| Eisai INC. | $181.87 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $165.87 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.42 | 2020-2025 | Caplyta |
| Penumbra, INC. | $165.23 | 2025 | Indigo System |
| Inspire Medical Systems, INC. | $161.18 | 2024 | Inspire |
| Medtronic, INC. | $157.19 | 2022 | |
| Supernus Pharmaceuticals, INC. | $154.64 | 2022-2024 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $150.99 | 2022 | |
| Cvrx, INC. | $145.18 | 2021 | |
| Gilead Sciences, INC. | $133.42 | 2019 | |
| Bausch Health US, LLC | $131.82 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $130.71 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Bard Peripheral Vascular, INC. | $122.51 | 2021 | |
| Tms Neurohealth Centers INC. | $122.50 | 2025 | Tms Neurohealth Centers INC. |
| Vifor Pharma, INC. | $114.90 | 2021 | |
| Biogen, INC. | $106.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $105.14 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $103.31 | 2021 | |
| Idorsia Pharmaceuticals US INC | $103.24 | 2023-2025 | Quviviq, Quviviq |
| Convatec INC. | $103.01 | 2023-2024 | |
| Mannkind Corporation | $100.52 | 2019-2022 | |
| Ibsa Pharma INC. | $88.85 | 2019-2023 | Tirosint, Licart |
| Althera Pharmaceuticals LLC | $86.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.04 | 2019 | |
| Genentech USA, INC. | $75.22 | 2019 | |
| Cleerly, INC. | $66.66 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Aytu Biopharma, INC. | $63.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.01 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $60.02 | 2021 | |
| Amneal Pharmaceuticals LLC | $50.70 | 2019-2022 | |
| Ardelyx, INC. | $40.52 | 2024 | Ibsrela |
| Medicure Pharma INC. | $39.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $34.52 | 2022 | |
| Alk-Abello, INC | $31.11 | 2024 | Grastek, Ragwitek, Odactra |
| Adlon Therapeutics L.P. | $30.48 | 2020 | |
| Globus Medical, INC. | $24.01 | 2025 | Senza |
| Aimmune Therapeutics, INC. | $24.00 | 2024 | |
| Dexcom, INC. | $22.53 | 2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $21.62 | 2023 | |
| Ironshore Pharmaceuticals INC. | $21.54 | 2024 | |
| Stryker Corporation | $21.43 | 2021 | |
| Shire North American Group INC | $19.36 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.22 | 2020 | |
| Shield Therapeutics INC | $18.76 | 2022 | |
| Horizon Therapeutics Plc | $17.48 | 2022 | |
| Nevro Corp. | $13.30 | 2022 | |
| Radius Health, INC. | $13.07 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.08 | 2020 | |
| Nabriva Therapeutics, Plc | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.